Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Kidney Neoplasms 1Graft vs Host Disease 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

Rituximab 2Sodium Chloride 1Pentostatin 1Monatide (IMS 3015) 1Magnetic Resonance Imaging 1Histamine Antagonists 1Exercise Test 1Epinephrine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Cyclophosphamide 1Cladribine 1Celecoxib 1Caves 1Bronchodilator Agents 1Biological Assay 1Bendamustine Hydrochloride 1Adrenal Cortex Hormones 1Acetaminophen 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm, Residual × Pentostatin × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡